The purpose of this study is to evaluate the safety and effectiveness of targeted immunotherapy in combination with ublituximab and umbralisib, in patients with advanced CLL or Richter's Transformation.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
27
A once daily oral agent
IV anti-CD20 monoclonal antibody
IV immunotherapy for cancer
TG Therapeutics Investigational Trial Site
New York, New York, United States
TG Therapeutics Investigational Trial Site
Durham, North Carolina, United States
TG Therapeutics Investigational Trial Site
Philadelphia, Pennsylvania, United States
TG Therapeutics Investigational Trial Site
Seattle, Washington, United States
Determine Acceptable Adverse Events That Are Related to Treatment
To determine the incidence of adverse events, any potential abnormal laboratory results and any dose-limiting toxicities
Time frame: 6 months of therapy
Overall Response Rate
The overall response rate (ORR) in patients with CLL and Richter's Transformation treated with Ublituximab in combination with Umbralisib and Targeted Immunotherapy
Time frame: Up to 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.